Cell Therapy News/Articles, page-17563

Thanks Phaedrus! I think we would agree that the company has lifted its game in corporate communication a lot in the last year, and more recently. However, it is still a complicated and rapidly evolving subject to navigate (cast your mind back to August/Sep last year) let alone communicate on not more than a page and a half. The company is also constrained by what it wants to say but can’t say in too much detail because it is dealing with the regulator. I hope a more diversified shareholder base with a sophisticated institutional following will develop if and when the first approval is given. However, I have a lot of admiration for people here who really do their own work to learn about the subject and share the knowledge. A big thank you! I’ve learnt a lot.